A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy. The quest to find a permanent solution to Duchenne muscular dystrophy (DMD) ...

None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of ...

Blood pressure and heart rate (pulse) are two important vital signs measured during a healthcare visit. Blood pressure (BP) is a measure of the force of blood on the blood vessel walls. Blood vessels ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

DMD was first described by French neurologist Guillaume Benjamin Amand Duchenne in the 1860s. However, until the 1980s, ...

New Study Investigates Effects of ADHD Medications on the Heart Apr. 7, 2025 — A new study has found that medications for ADHD have overall small effects on blood pressure and heart rate after ...

Right-sided heart failure develops when the right side of the heart is too weak to pump blood to the lungs. This causes blood to back up into the venous system, limiting how much blood the heart can ...

Elevidys was granted expanded approval by the U.S. Food and Drug Administration in 2024, with expectations high that the therapy, designed to restore a critical muscle protein called dystrophin ...

Credit: Shutterstock / Dan76. Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy (DMD). Results ...

DALLAS—Patients with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44) who were treated with delpacibart zotadirsen (AOC 1044) demonstrated statistically significant ...

Without dystrophin, your muscle cells remain unprotected ... Children who show symptoms at a younger age are at a higher risk of heart problems than those who show symptoms later.